Aurora Spine reported 4Q18 revenue of USD $2.5MM, +82.4% vs. 4Q17, with full-year 2018 revenue of $8.7MM, +44.5% vs. 2017.
- Record year, with highest revenue in company’s history
- Integrated more products into Screwless Procedure, a surgical approach to spinal fusion that includes ZIP MIS Fusion Systems, TiNano Interbody cages and COMPASS 4D MIS lateral retractor system
- Acquired exclusive license to EASiFX SI fusion implant and surgical method from SILIF in November 2018
- Granted European patent for ZIP Ultra in October 2018
- Reached 100th Canadian surgical implant of ZIP Ultra in July 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows ($MM).
4Q18 | 4Q17 | $ Chg | % Chg | |
Spine | $2.3 | $1.3 | $1.1 | 81.5% |
Orthobiologics | $0.1 | $0.1 | $0.1 | 99.0% |
Total | $2.5 | $1.4 | $1.1 | 82.4% |
FY18 | FY17 | $ Chg | % Chg | |
Spine | $8.2 | $5.7 | $2.5 | 43.7% |
Orthobiologics | $0.5 | $0.3 | $0.2 | 57.6% |
Total | $8.7 | $6.0 | $2.7 | 44.5% |
Net earnings are as follows.
FY18 | Amount ($MM) | % of Sales |
Sales | $8.7 | |
Cost of Sales | -$4.1 | 47.1% |
General and Admin | -$2.9 | 33.1% |
Marketing | $0.0 | 0.5% |
R & D | $0.0 | 0.4% |
Other | -$1.7 | 19.6% |
Net Earnings | -$0.1 | -0.8% |
Sources: Aurora Spine Corporation; ORTHOWORLD estimates
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Aurora Spine reported 4Q18 revenue of USD $2.5MM, +82.4% vs. 4Q17, with full-year 2018 revenue of $8.7MM, +44.5% vs. 2017.
Record year, with highest revenue in company’s history
Integrated more products into Screwless Procedure, a surgical approach to spinal fusion that includes ZIP MIS Fusion Systems, TiNano Interbody cages and...
Aurora Spine reported 4Q18 revenue of USD $2.5MM, +82.4% vs. 4Q17, with full-year 2018 revenue of $8.7MM, +44.5% vs. 2017.
- Record year, with highest revenue in company’s history
- Integrated more products into Screwless Procedure, a surgical approach to spinal fusion that includes ZIP MIS Fusion Systems, TiNano Interbody cages and COMPASS 4D MIS lateral retractor system
- Acquired exclusive license to EASiFX SI fusion implant and surgical method from SILIF in November 2018
- Granted European patent for ZIP Ultra in October 2018
- Reached 100th Canadian surgical implant of ZIP Ultra in July 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows ($MM).
4Q18 | 4Q17 | $ Chg | % Chg | |
Spine | $2.3 | $1.3 | $1.1 | 81.5% |
Orthobiologics | $0.1 | $0.1 | $0.1 | 99.0% |
Total | $2.5 | $1.4 | $1.1 | 82.4% |
FY18 | FY17 | $ Chg | % Chg | |
Spine | $8.2 | $5.7 | $2.5 | 43.7% |
Orthobiologics | $0.5 | $0.3 | $0.2 | 57.6% |
Total | $8.7 | $6.0 | $2.7 | 44.5% |
Net earnings are as follows.
FY18 | Amount ($MM) | % of Sales |
Sales | $8.7 | |
Cost of Sales | -$4.1 | 47.1% |
General and Admin | -$2.9 | 33.1% |
Marketing | $0.0 | 0.5% |
R & D | $0.0 | 0.4% |
Other | -$1.7 | 19.6% |
Net Earnings | -$0.1 | -0.8% |
Sources: Aurora Spine Corporation; ORTHOWORLD estimates
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.